Updates and Statements | Pfizer

Skip to main content

Science
Products
Stories
Newsroom
About

Investors Careers Media Partners

Careers
Investors

How can we help you?

4602 search results for

Suggestions within Pfizer.com

Home

Newsroom

Updates and Statements

Updates and Statements

Year

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

Month

January

February

March

April

May

June

July

August

September

October

November

December

View 12

View 24

View 48

Keywords

All Keywords

April 2022

04.08.2022 MedicinesVaccines Three Year Follow-Up Data from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) Confirm Prolonged Progression-Free Survival in First-Line ALK-Positive Advanced Lung Cancer

March 2022

03.21.2022 Medicines Pfizer Voluntary Nationwide Recall of Lots of ACCURETIC™ (quinapril HCl/hydrochlorothiazide), quinapril and hydrochlorothiazide Tablets, and quinapril HCl/hydrochlorothiazide Tablets Due to N-Nitroso- Quinapril Content
03.15.2022 Covid-19Vaccines Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults
03.14.2022 Responsibility Pfizer Updates Company Position in Russia

February 2022

02.25.2022 Partnerships FDA Accepts for Review Pfizer’s Supplemental Application for ABRILADA™ (adalimumab-afzb) InterchangeabilityFDA Accepts for Review Pfizer’s Supplemental Application for ABRILADA™ (adalimumab-afzb) Interchangeability
02.24.2022 Partnerships Pfizer and BioNTech Receive Positive CHMP Opinion for COVID-19 Vaccine Booster in Adolescents 12 through 17 Years of Age in the European Union
02.24.2022 Covid-19Vaccines Pfizer and BioNTech Receive Positive CHMP Opinion for COVID-19 Vaccine Booster in Adolescents 12 through 17 Years of Age in the European Union
02.23.2022 Vaccines CDC Advisory Committee on Immunization Practices Votes to Recommend TicoVac™, Pfizer’s Tick-Borne Encephalitis (TBE) Vaccine, For Those at Risk of Virus Exposure

December 2021

12.20.2021 Partnerships Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply
12.17.2021 Partnerships Pfizer and BioNTech Provide Update on Ongoing Studies of COVID-19 Vaccine
12.16.2021 Covid-19Vaccines Pfizer and BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of COMIRNATY® in Adolescents 12 Through 15 Years of Age
12.03.2021 Medicines FDA Issues Update to XELJANZ® Prescribing Information in the United States

Page 3
Page 4
Current page 5
Page 6
Page 7

Investors
Careers
Media
Partners

Grant Seekers
Healthcare Professionals
Business to Business
Merchandise

Privacy Statement
Terms of Use
Contact Us

© 2023 Pfizer Inc. All rights reserved

This information—including product information—is intended only for residents of the United States.

The products discussed herein may have different labeling in different countries.

Twitter
Facebook
Linked In
Instagram
Youtube